Literature DB >> 1652776

Insulin-like growth factor I (IGF-I) receptors and IGF-I action in oligodendrocytes from rat brains.

B A Masters1, H Werner, C T Roberts, D LeRoith, M K Raizada.   

Abstract

Oligodendrocyte progenitor cells were prepared by mechanical dissociation of 1-day-old rat brain cultures. These cells undergo proliferation and differentiation into oligodendrocytes as demonstrated by the expression of proliferation and differentiation-related specific antigens. We have used this unique culture system to characterize insulin-like growth factor I (IGF-I) receptors and their action in the central nervous system (CNS). 125I-IGF-I specifically binds to these cultures with high affinity. Competition-inhibition data suggest that IGF-I is most potent in competing for 125I-IGF-I binding, followed by IGF-II and insulin. Scatchard analyses of the binding data indicate a curvilinear plot with a Kd for high affinity of 0.2 nM, and a Bmax of 247 fmol/mg, and a Kd for low affinity of 3.2 nM and Bmax of 1213 fmol/mg protein. Covalent cross-linking followed by SDS-PAGE analysis demonstrated a radioactive band of Mr 135,000 which corresponds to the alpha subunit of the IGF-I receptor. Solution hybridization/RNase protection assay produced a single protected band corresponding to IGF-I receptor messenger RNA, further confirming the presence of these receptors. Incubation of progenitor cells with IGF-I resulted in a time- and concentration-dependent increase in [3H]thymidine incorporation and cell numbers. This effect appears to be mediated by IGF-I receptors since IGF-II and insulin were proportionately less potent. In addition to its effect on proliferation, IGF-I also increased the number of 4E7- and GC-antigen positive cells. These observations indicate that oligodendrocytes in primary culture express specific IGF-I receptors and that the interaction of IGF-I with these receptors results in the proliferation as well as differentiation of oligodendrocytes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1652776     DOI: 10.1016/0167-0115(91)90207-w

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  7 in total

Review 1.  Neurodevelopmental effects of insulin-like growth factor signaling.

Authors:  John O'Kusky; Ping Ye
Journal:  Front Neuroendocrinol       Date:  2012-06-16       Impact factor: 8.606

Review 2.  Macrophages in CNS remyelination: friend or foe?

Authors:  L T Diemel; C A Copelman; M L Cuzner
Journal:  Neurochem Res       Date:  1998-03       Impact factor: 3.996

3.  Insulin-like growth factor type 1 receptor signaling in the cells of oligodendrocyte lineage is required for normal in vivo oligodendrocyte development and myelination.

Authors:  Martha Zeger; Greg Popken; Jihui Zhang; Shouhong Xuan; Q Richard Lu; Markus H Schwab; Klaus-Armin Nave; David Rowitch; A Joseph D'Ercole; Ping Ye
Journal:  Glia       Date:  2007-03       Impact factor: 7.452

Review 4.  TGF-β Family Signaling in Embryonic and Somatic Stem-Cell Renewal and Differentiation.

Authors:  Alan C Mullen; Jeffrey L Wrana
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-07-05       Impact factor: 10.005

Review 5.  The role of the insulin-like growth factors in the central nervous system.

Authors:  A J D'Ercole; P Ye; A S Calikoglu; G Gutierrez-Ospina
Journal:  Mol Neurobiol       Date:  1996-12       Impact factor: 5.590

Review 6.  The impact of trophic and immunomodulatory factors on oligodendrocyte maturation: Potential treatments for encephalopathy of prematurity.

Authors:  Josine E G Vaes; Myrna J V Brandt; Nikki Wanders; Manon J N L Benders; Caroline G M de Theije; Pierre Gressens; Cora H Nijboer
Journal:  Glia       Date:  2020-11-30       Impact factor: 7.452

7.  Intranasal mesenchymal stem cell therapy to boost myelination after encephalopathy of prematurity.

Authors:  Josine E G Vaes; Caren M van Kammen; Chloe Trayford; Annette van der Toorn; Torben Ruhwedel; Manon J N L Benders; Rick M Dijkhuizen; Wiebke Möbius; Sabine H van Rijt; Cora H Nijboer
Journal:  Glia       Date:  2020-10-12       Impact factor: 7.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.